PTPN11 and cancer: Many well-studied mutations in this region exclusively disrupt the auto-inhibitory interface, with a nominal effect on SHP2PTP activity (e.g. cancer mutations at R265 and S502, which interact with E76 in auto-inhibited SHP2).